Wealth manager Ken Mathieson is the managing director of Laidlaw Asset Management, LLC in New York. With over 30 years of experience in the financial services industry, Ken Mathieson oversees Laidlaw’s wealth management and investment banking operations. He was recently involved in Laidlaw’s book-running management of Hoth Therapeutics’ public offering.
Hoth Therapeutics, a clinical-stage biopharmaceutical, is working on new therapies to help people with dermatological disorders. The company has several therapies in its pipeline that could improve the lives of people with atopic dermatitis, psoriasis, chronic wounds, and acne.
On March 2020, Hoth announced the pricing of its public offer of 1,449,275 shares of common stock for $3.45 a share. The company expected to raise $5 million from the public offering. The balance, after deducting underwriting discount and offering expenses, would be used to develop therapies against the Corona virus and to support internal operations like administration and marketing.
Hoth had previously filed a shelf registration statement on Form S-3 with the SEC which was declared effective on March 11. It followed up by filing preliminary and accompanying prospectuses with the federal agency on March 23. Both are available on the SEC’s website.
Besides Laidlaw, other companies involved in the public offering are The Benchmark Company LLC, the qualified independent underwriter, and Roth Capital Partners, Hoth’s financial advisor.
Laidlaw Asset Management Founding Partner Ken Mathieson 
You must be logged in to post a comment.